Iskalni niz je ali predolg ali pa vsebuje preveč besed.
Prevodi: sl > en
1–9/9
N0
1 Pravna redakcija
DRUGO
dušik po Kjeldahlovi metodi (razen N0 3 )
Nitrogen by Kjeldahl method (except N03)
2 Pravna redakcija
obramba
CELEX: 31993R0793
[2-(akriloiloksi)etil]trimetilamonijev klorid C 8 H 16 N0 2 ·Cl
[2-(acryloyloxy)ethyl]trimethylammonium chloride C 8 H 16 N0 2 ·Cl
3 Pravna redakcija
DRUGO
[2-(akriloiloksi)etil]trimetilamonijev klorid C 8 H 16 N0 2 ·Cl
[2-(acryloyloxy)ethyl]trimethylammonium chloride C 8 H 16 N0 2 ·Cl
4 Prevajalska redakcija
izobraževanje
CELEX: 31992L0069
N0 = število celic/ml ob času t0 (začetek preskusa),
N0 = number of cells/ml at time t0 (beginning of the test),0,
5 Prevajalska redakcija
izobraževanje
CELEX: 31992L0069
Ac = površina med rastno krivuljo kontrolne kulture in vodoravno premico N = N0.
Ac = area between the control growth curve and the horizontal line N = N0.
6 Prevajalska redakcija
izobraževanje
CELEX: 31992L0069
At = površina med rastno krivuljo pri koncentraciji t in vodoravno premico N = N0.
At = area between the growth curve at the concentration t and the horizontal line N = N0.
7 Prevajalska redakcija
izobraževanje
CELEX: 31992L0069
Površina med rastno krivuljo in vodoravno premico N = N0 se lahko izračuna po naslednji enačbi: A = N + N - 2N × N + N - 2N ×
The area between the growth curves and the horizontal line N = N0 may be calculated according to the formula:
8 Prevajalska redakcija
RS
EMEA
Bikalutamid v odmerku 150 mg je bil proučevan kot terapija za bolnike z lokaliziranim (T1- T2, N0 ali NX, M0) ali lokalno napredovalim (T3- T4, katerikoli N, M0; T1- T2, N+, M0) nemetastatskim rakom prostate v kombinirani analizi treh s placebom kontroliranih, dvojno slepih študij pri 8113 bolnikih. Bikalutamid je bil uporabljen kot takojšnja hormonska terapija ali kot adjuvantna terapija poleg radikalne prostatektomije ali radioterapije (v prvi vrsti z zunanjim obsevanjem).
Bicalutamide 150 mg was studied as a treatment for patients with localized (T1-T2, N0 or NX, M0) or locally advanced (T3-T4, any N, M0; T1-T2, N+, M0) non-metastatic prostate cancer, in a combined analysis of 3 placebo-controlled double-blind studies in 8,113 patients, where the product was given as immediate hormone therapy or as adjuvant to radical prostatectomy or radiotherapy (primarily external beam radiation).
9 Prevajalska redakcija
RS
EMEA
CASODEX (bikalutamid) 150 mg je bil preučevan kot terapija za bolnike z lokaliziranim (T1– T2, N0 ali NX, M0) ali lokalno napredovalim (T3– T4, katerikoli N, M0; T1– T2, N+, M0) nemetastatskim rakom prostate v kombinirani analizi treh s placebom kontroliranih, dvojno slepih študij pri 8113 bolnikih. CASODEX je bil uporabljen kot takojšnja hormonska terapija ali kot adjuvantna terapija poleg radikalne prostatektomije ali radioterapije (v prvi vrsti z zunanjim obsevanjem).
CASODEX (Bicalutamide) 150 mg was studied as a treatment for patients with localised (T1-T2, N0 or NX, M0) or locally advanced (T3-T4, any N, M0; T1-T2, N+, M0) non-metastatic prostate cancer in a combined analysis of 3 placebo controlled double-blind studies in 8113 patients, where CASODEX was given as immediate hormonal therapy or as adjuvant to radical prostatectomy or radiotherapy, (primarily external beam radiation).
Prevodi: sl > en
1–9/9
N0